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Abstract
The role of N-glycosylation in reduced folate carrier (RFC) transport and membrane targeting was examined in transport-
deficient K562 (K500E) cells transfected with human RFC cDNAs. Treatment of cells expressing wild-type RFC with
tunicamycin (0^3 Wg) resulted in a progressive shift of the V85 kDa RFC on western blots to 65 kDa. At 3 Wg/ml
tunicamycin, the nearly complete loss of glycosylated RFC was accompanied by a V25% decreased rate of methotrexate
uptake. A deglycosylated RFC cDNA construct in which asparagine-58 was replaced by glutamine (Gln58-RFC) was
expressed in K500E cells as a 65 kDa protein and restored transport capacity for methotrexate and (6S)5-formyl
tetrahydrofolate. With both wild-type and Gln58-RFC constructs, expression of cDNA-encoded RFC protein far exceeded
relative levels of RFC uptake. Wild-type and Gln58-RFCs containing a hemagglutinin (HA) epitope at the carboxyl terminus
were similarly functional and, by immunofluorescence staining with rhodamine-conjugated anti-HA antibody, were localized
to plasma membranes. Collectively, our results demonstrate that N-glycosylation of human RFC plays no significant role in
either transport function or membrane targeting. The discrepancy between the stoichiometries of RFC expression and
transport activity for both wild-type RFC and Gln58-RFC implies that identical regulatory controls and/or non-RFC
transport components are necessary to completely restore transport function in the transfected cells. ß 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Methotrexate (Mtx) continues to be widely used as
an antitumor agent for a variety of malignancies in-
cluding leukemias, breast cancer, head and neck can-
cer, lymphomas, and choriocarcinoma [1]. E⁄cient
membrane transport of Mtx by the reduced folate
carrier (RFC) is essential for attaining an intracellu-
lar level of free drug su⁄cient to exert maximal in-
hibition of its intracellular target, dihydrofolate re-
ductase [2,3]. Futhermore, impaired Mtx transport
associated with decreased RFC expression or muta-
tions of the RFC protein is a major mechanism of
Mtx resistance in cultured cells and patient speci-
mens [4^7].
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With the isolation and characterization of cDNAs
for RFC [8^13], it now becomes feasible to investi-
gate the functional roles of individual amino acids
and post-translational modi¢cations that may in£u-
ence transport activity. The human RFC was origi-
nally suggested to di¡er from the murine transporter
in its N-glycosylation [14], and consistent with this
notion, a single N-glycosylation consensus site occurs
at asparagine-58 in the predicted amino acid se-
quence for human RFC [10^13]. When expressed in
transport-impaired K562 (K500E) cells, the cDNA-
encoded protein can be enzymatically deglycosylated
[15]. However, the importance of this modi¢cation to
the intracellular routing and function of the human
RFC has not been rigorously con¢rmed. In this com-
munication, we explore this important question in
K500E transfectants expressing human RFC cDNA
constructs, through the use of the N-glycosylation
inhibitor, tunicamycin (TN; [16]), and site-directed
mutagenesis.
2. Materials and methods
2.1. Chemicals
[3P,5P,7-3H]Mtx (20 Ci/mmol) and [3P,5P,7,9-
3H](6S)5-formyl tetrahydrofolate (20 Ci/mmol) were
purchased from Moravek Biochemicals (Brea, CA)
and puri¢ed prior to use by reverse phase HPLC
[17]. Unlabeled Mtx, (6,R,S)5-formyl tetrahydrofo-
late, and TN were obtained from the Drug Develop-
ment Branch, National Cancer Institute, Bethesda,
MD.
2.2. Cell culture
The K562 erythroleukemia line was obtained from
the American Type Culture Collection (Rockville,
MD). Cells were maintained in RPMI 1640 contain-
ing 10% heat-inactivated iron-supplemented calf se-
rum (Hydore), 2 mM L-glutamine, 100 U/ml penicil-
lin, and 100 Wg/ml streptomycin, in a humidi¢ed
atmosphere at 37‡ in the presence of 5% CO2/95%
air. The transport-de¢cient K500E subline was se-
lected from wild-type K562 cells by cloning in soft
agar in the presence of 500 nM Mtx as previously
described [15]. The K43-6 subline was derived from
K500E cells by transfecting the full-length human
RFC cDNA (KS43) constructed in a pCDNA3 ex-
pression vector [15]. The characteristics of these cells
including levels of RFC expression and transport
kinetics were previously described [15].
2.3. Preparation of Gln58-RFC and transfection of
K500E cells
Nucleotides 171^174 encoding Asn58 (AAC) in the
full length KS43 human RFC cDNA [10] were
changed to CAG, which encodes for Gln, using a
PCR-based site-directed mutagenesis strategy. The
mutation primers were 5P-TCCTGGGGCCCGA-
CAAGCAGTTCAC (nucleotide positions 155^179,
position 1 is the translation start) and 5P-GCCAGC-
GAGATGTAGTTGAGCGT (positions 572^550).
Following ampli¢cation, the 417 bp PCR product
was puri¢ed, digested with ApaI (cleaves within the
mutation primer) and NcoI (cleaves at position 386^
391), and ligated into ApaI/NcoI-digested KS43 RFC
in pBluescript (SK3). The complete RFC coding re-
gion was excised by BamHI and XhoI digestions and
inserted into a BamHI/XhoI-digested pCDNA3 ex-
pression vector to generate the Gln58-RFC construct.
The Gln58-RFC construct was transfected into the
transport-de¢cient K500E subline using lipofectin
(Gibco) and G418 selection as previously described
[15]. Positive clones expressing moderate and high
levels of Gln58-RFC protein (KEDG1 and
KEDG9, respectively) were identi¢ed by Western
blotting.
2.4. Western analysis of RFC proteins
For the analysis of RFC structures in TN-treated
cells, a particulate membrane fraction was prepared
by di¡erential centrifugation [14]. For the character-
ization of the mutagenized RFC constructs stably
expressed in K500E cells, the particulate membrane
fractions were additionally puri¢ed on discontinuous
sucrose gradients [14]. Membrane proteins were elec-
trophoresed on 7.5% polyacrylamide gels in the pres-
ence of SDS [18] and electroblotted onto PVDF
membranes (DuPont). RFC proteins were detected
by chemiluminescence (Pierce, Rockford, IL) using
a protein A-puri¢ed RFC speci¢c peptide antibody
(RFC/ps, [19]), or antibody prepared in rabbits to a
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glutathione S-transferase (GST)-RFC fusion protein,
expressed in Escherichia coli and puri¢ed by gluta-
thione-Sepharose 4B chromatography (S.C. Wong,
L. Zhang, S.A. Proefke, T.L. Radewan, A. Bhushan,
and L.H. Matherly, manuscript submitted). Light
emission was recorded on X-ray ¢lm with various
exposure times to avoid overexposure. Signals were
analyzed using a computing densitometer and Image-
Quant software (Molecular Dynamics, Sunnyvale,
CA).
2.5. Preparation of epitope-tagged RFC and immuno-
localization of HA-RFC proteins
A hemagglutinin (HA) peptide epitope (YPYDVP-
DYASL, [20]) was fused to the human RFC carboxyl
terminus by PCR-based site-directed mutagenesis.
The downstream primer used for introducing the
HA epitope was 5P-GGTACCTCGAGTCAGAGG-
CTAGCGTAATCCGGAACATCGTATGGGTAC-
TGAACACCGTCGCTTGGAA. A XhoI restriction
site was included for subcloning. The upstream RFC
speci¢c primer used was 5P-CCTGGTCTTCGGGG-
TCAACA (positions 1191^1211 in KS43 RFC
cDNA). The PCR product was puri¢ed, digested
with XhoI and EcoRI (positions 1603^1608), and li-
gated into EcoRI/XhoI-digested KS43 in pCDNA3
[10] to generate the HA-RFC plasmid construct. A
carboxyl HA-tagged Gln58-RFC construct (HA/
Gln58-RFC) was prepared in an identical fashion us-
ing EcoRI/XhoI-digested Gln58-RFC for ligation.
Both the HA-RFC and HA/Gln58-RFC constructs
in pCDNA3 were transfected into K500E cells, as
described above. Based on the level of RFC expres-
sion on Western blots, HA8 (expresses HA-RFC)
and HA-DG32 (expresses HA/Gln58-RFC) sublines
were selected for further studies.
A commercially available rhodamine-conjugated
anti-HA monoclonal antibody (12CA5; Boehringer
Mannheim) was used to localize HA-tagged RFC
proteins by immuno£uorescence. HA8, HA-DG32
and K500E cells (5^10U106) were washed in ice-
cold PBS and ¢xed in 2 ml of 3.3% paraformalde-
hyde in PBS on ice for 30 min. Cells were washed
twice in PBS and permeabilized in 2 ml of 0.1%
Triton X-100 in PBS for 5 min at 4‡C. Permeabilized
cells were washed (2U) in PBS and samples
(2.5U106 cells) incubated in 1 ml of PBS containing
1% bovine serum albumin and 5 Wg of rhodamine-
conjugated 12CA5 antibody for 1 h at 4‡C. Fluores-
cent-labeled cells were washed (2U) in PBS and re-
suspended at a density of 50 000 cells/ml; 200 Wl of
cells were cytocentrifuged onto microscope slides,
mounted with one drop of ‘SlowFade’ antifade re-
agent (Molecular Probes) and sealed with cover slips.
Slides were observed under a Zeiss laser scanning
microscope 310 at 543 nm and 630U magni¢cation.
2.6. Membrane transport measurements
Initial uptake rates for [3H]Mtx and [3H](6S) 5-
formyl tetrahydrofolate were determined over 180 s
as previously described [14], using 0.5^1U107 cells/
ml. The levels of intracellular radioactivity were ex-
pressed as pmol/mg protein, calculated from direct
measurements of radioactivity and protein contents
of the cell homogenates. Protein assays were by the
method of Lowry et al. [21]. Kinetic constants (Kt
and Vmax values) were calculated from Lineweaver^
Burk plots from initial uptake rates over a range of
substrate concentrations.
3. Results and discussion
Oligosaccharide side chains of membrane proteins
have been shown in many instances to be important
for proper function, membrane targeting and trans-
membrane signaling [22]. TN, an inhibitor of core
oligosaccharide addition to asparagine residues of
nascent glycoproteins [16], was initially used to assess
the roles of N-linked glycosylation in RFC-mediated
Mtx transport and membrane targeting. K43-6 trans-
fectants, expressing increased levels of human RFC
[15], were cultured with 0, 1, 2 and 3 Wg/ml of TN
over 16 days (10^11 generations), after which cells
were harvested for Western analysis of RFC protein
in particulate membrane and soluble fractions, and
assays of [3H]Mtx uptake. A dose-dependent inhib-
ition of N-glycosylation was clearly evident with in-
creasing TN, as indicated by the progressive shift
of the broadly-migrating RFC band (centered at
V85 kDa for the gel in Fig. 1, left panel) in the
particulate fraction to a condensed band at 65 kDa.
This is the size predicted from the RFC coding se-
quence [10]. At 3 Wg/ml TN, almost all membrane
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RFC protein was deglycosylated (Fig. 1, left panel).
Immunoreactive RFCs were virtually undetectable in
the soluble fraction in TN-treated cells, even when
3-fold more protein was analyzed, suggesting that
there was no e¡ect on membrane localization (Fig.
1, right panel). While treatments of K43-6 cells with
1 or 2 Wg/ml TN had no e¡ect on initial uptake of
[3H]Mtx (at 0.5 WM) over 180 s, the nearly complete
loss of N-glycosylated RFC at 3 Wg/ml TN was ac-
companied by a V25% decreased Mtx uptake rate
(data not shown).
Although TN treatments had negligible e¡ects on
cell proliferation, secondary metabolic e¡ects includ-
ing inhibition of protein synthesis [16] or e¡ects on
non-RFC glycosylation could compromise analysis
of changes in Mtx transport in TN-treated cells. To
obviate this concern, we used site-directed mutagen-
esis to replace Asn58 with Gln, thereby eliminating
the N-glycosylation consensus site in the resulting
Gln58-RFC construct. In order to assess the plasma
membrane localization of wild-type and Gln58-RFCs,
additional RFC constructs were prepared in which
an HA peptide epitope was inserted into the RFC
carboxyl terminus. HA-RFC, HA/Gln58-RFC, and
Gln58-RFC constructs were all transfected into trans-
port-de¢cient K500E cells and stable clones (HA8,
HA-DG32, and KEDG1 and KEDG9, respectively;
Table 1) selected for further analysis.
Initial rates of [3H]Mtx uptake were measured for
the transfected lines and compared to wild-type
K562, untransfected K500E cells, and the K43-6
transfectants expressing wild-type RFC [15]. For all
the RFC transfectants, Mtx uptake equaled
(KEDG1) or slightly exceeded (K43-6, KEDG9,
HA8, HA-DG32) the level for wild-type K562 cells,
and exceeded that in K500E cells by 6.6^24.9-fold
(Table 1). There were no di¡erences in either Vmax
or Kt values for Mtx between the K500E transfec-
tants expressing glycosylated (K43-6) and Gln58-
(KEDG9) RFCs, or carboxyl HA-RFC (HA8) (Ta-
ble 2). Likewise, relative uptake of [3H](6S)5-formyl
tetrahydrofolate (at 0.5 WM) varied only slightly (less
than 2-fold) between wild-type K562, K43-6,
KEDG9, and HA8 cells (not shown).
On Western blots of puri¢ed plasma membrane
proteins, Gln58- and HA/Gln58-RFCs both appeared
as 65 kDa bands (KEDG1 and 9, and HA-DG32,
Table 1
Mtx uptake rates and relative RFC expression in K562 sublinesa
Cell line RFC constructb Uptakec (pmol/mg/min) Relative uptaked Relative RFC expressione
K500E ^ 0.15 þ 0.03 0.18 0.03
K562 ^ 0.85 þ 0.07 1.00 1.00
K43-6 KS43 2.99 þ 0.36 3.52 20.00
KEDG1 Gln58-RFC 1.00 þ 0.07 1.18 4.00
KEDG9 Gln58-RFC 2.44 þ 0.11 2.87 39.00
HA8 HA-RFC 3.62 þ 0.10 4.26 144.65
HA-DG32 HA/Gln58-RFC 3.81 þ 0.27 4.48 41.60
aUptake of 0.5 WM [3H]Mtx was measured as described in Section 2.
bThe RFC constructs are KS43 (wild-type RFC), Gln58-RFC (RFC containing Gln for Asn58); HA-RFC (RFC containing a carboxyl
terminal HA epitope), and HA/Gln58-RFC (RFC containing glutamine for asparagine-58 and a carboxyl terminal HA epitope).
cUptake values are reported as mean values þ S.E.M from two to three experiments.
dRelative Mtx uptake compared to wild-type K562 cells.
eRelative RFC expression was normalized to RFC signal measured by densitometry per Wg membrane protein.
Fig. 1. Inhibition of RFC glycosylation by TN. Particulate
membrane (30 Wg) and soluble (100 Wg) proteins from K43-6
cells, cultured in the presence of TN (0, 1, 2 or 3 Wg/ml) for 16
days, were fractionated on a 7.5% gel in the presence of SDS
and electroblotted onto a PVDF membrane. Detection was
with an anti-RFC peptide antibody (RFC/ps; [19]) and an en-
hanced chemiluminescence kit. Migrations of the molecular
weight markers are indicated.
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respectively), clearly distinguishable from the glyco-
sylated RFC forms in K43-6 and HA8 cells (Fig. 2).
By immuno£uorescence staining with rhodamine-
conjugated 12CA5 antibody, both HA8 and HA-
DG32 cells exhibited prominent rhodamine staining
localized to the cell membranes (Fig. 3D and F, re-
spectively), indicating that the lack of N-glycosyla-
tion has no e¡ect on RFC membrane targeting.
Although low level staining was also detected in
K500E cells, there was no speci¢c staining of the
plasma membrane surface (Fig. 3B).
We previously reported [15] that K43-6 cells exhib-
it a disparate level of RFC protein (V20-fold in-
creased over wild-type cells in Fig. 2) to restored
Mtx transport, and analogous results were obtained
for the Gln58- and HA-RFC constructs (Fig. 2 and
Table 1). Levels of maximal Mtx uptake were nearly
identical in the transfected lines (V3^4-fold over
wild-type) regardless of levels of RFC expression.
When Mtx uptake was normalized to RFC expres-
sion for the transfectants, relative levels ranged from
0.029 to 0.30 and clearly showed that neither the
Gln58- nor HA-modi¢cations of RFC appreciably
altered transport function compared to wild-type
RFC.
Hence, our results demonstrate that inhibition of
human RFC N-glycosylation by treatment with TN,
or elimination of the RFC N-glycosylation consensus
site by site-directed mutagenesis has little or no sig-
ni¢cant e¡ect on either transport function or mem-
brane targeting for the human RFC. In spite of high
levels of surface expression, for both glycosylated
and non-glycosylated carriers, the low e⁄ciency of
the restored transport approximates only 3^30% of
that expected from the levels of immunoreactive
RFCs. Indeed, our results add to the growing list
of discordant properties between transfected and en-
dogenous RFCs, including speci¢cities for transport
Table 2
Kinetic constants for Mtx in£uxa
Cell line Vbmax (pmol/mg/min) K
b
t (WM)
K562 5.93 þ 1.05 3.07 þ 0.40
K43-6 10.74 þ 0.38 1.65 þ 0.20
KEDG9 9.04 þ 1.26 1.49 þ 0.22
HA8 10.86 þ 1.91 1.16 þ 0.23
aKinetic constants for Mtx transport were calculated by Line-
weaver^Burk analysis.
bVmax and Kt values are reported as mean values þ S.E.M.
(n=2).
Fig. 2. Western blotting of glycosylation-defective mutant RFCs and epitope-tagged RFCs in transfected K500E cells. Sucrose gra-
dient-puri¢ed membrane proteins from Gln58- and HA-RFC transfectants (KEDG1, KEDG9, HA8 and HA-DG32), wild-type RFC
transfectants (K43-6), and untransfected K500E and wild-type K562 cells were fractionated on a 7.5% gel in the presence of SDS and
electroblotted onto a PVDF membrane. Detection was with anti-GST-RFC antibody and an enhanced chemiluminescence kit. The
amounts of membrane protein analyzed for each line and the molecular standards are noted. A and B are from the same Western
blot exposed to X-ray ¢lm for di¡erent times. The bands representing the full-size RFC, Gln58-RFC, HA-RFC, and HA/Gln58-RFC
are noted.
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substrates [10,23,24], pH optima [23^25], and bidirec-
tional transport £uxes for Mtx [26]. Collectively,
these di¡erences suggest a complex modulation of
transporter function which distinguishes endoge-
nously-expressed from transfected RFCs, and involv-
ing as-yet uncharacterized regulatory controls and/or
requirements for non-RFC transport components
[15].
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